BluePoint Partners

BluePoint Partners is a Korean early-stage venture and accelerator firm based in Daejeon, the city that anchors Korea’s most concentrated cluster of public research universities and government-funded laboratories. That location is structural to the firm’s thesis. BluePoint specializes in highly technical, science-backed startups emerging from Korean academic institutions, with a portfolio that emphasizes biotech, medical devices, and broader deep tech rather than the consumer or software-driven companies that dominate Seoul-headquartered seed funds.

The healthcare thesis at BluePoint is research-translation oriented. The firm backs founders who are typically academic researchers, postdoctoral scientists, or recent PhDs commercializing technology developed in university or government laboratories, and the team’s diligence and operational support are calibrated to that founder profile. Areas of activity include therapeutic platforms, novel medical devices, diagnostic technologies, and broader deep tech with healthcare applications. AI fits within scope when it is deeply technical and grounded in original research rather than applied to existing software categories. The team is comfortable being the first institutional investor for a company that is still in the technology development phase and has not yet identified its primary commercial application with full clarity.

Check sizes are typically 250 thousand to one million dollars at entry, with the firm participating at pre-seed and seed and follow-on capacity into Series A in higher-conviction positions. Geographic focus is primarily Korea, with concentration around the Daejeon research ecosystem and broader engagement with founders coming out of KAIST, government research institutes, and other Korean technical universities. The firm’s accelerator program complements its investment activity, providing portfolio companies with structured early-stage support that combines capital with operating guidance.

The team includes partners with backgrounds in technical research and Korean venture, supported by an accelerator infrastructure and a network of advisors drawn from the Daejeon research community. The combination is unusual in Korean venture, where most early-stage firms are concentrated in Seoul and oriented toward software and consumer rather than science.

For founders, BluePoint Partners is most useful when the company is being built on substantial scientific or technical IP that requires a patient and informed early investor. The firm’s introductions to other Korean institutional investors, government R&D programs, and downstream Series A investors are particularly valuable for companies that need a credible bridge from research to commercial venture funding. Post-investment engagement includes accelerator program participation and active partner involvement in early company-building decisions, hiring, and fundraising strategy. Founders coming from non-research backgrounds or building software companies with conventional commercial trajectories will find the firm’s posture less aligned, but for Korean deep tech and biotech founders translating academic research into venture-scale companies, BluePoint is one of the more deliberately positioned early-stage firms in the country.